Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023GlobeNewsWire • 10/31/23
Evoke Pharma's Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 AnGlobeNewsWire • 10/18/23
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) MeetingGlobeNewsWire • 08/07/23
Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual MeetingGlobeNewsWire • 07/25/23
Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its TreatmentGlobeNewsWire • 06/14/23
Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare ResourcesGlobeNewsWire • 05/09/23
Evoke Pharma's Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023GlobeNewsWire • 05/04/23
United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTIGlobeNewsWire • 04/20/23
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related PatentGlobeNewsWire • 04/06/23
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023GlobeNewsWire • 03/23/23
Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023GlobeNewsWire • 03/15/23
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary SessionGlobeNewsWire • 02/21/23
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023GlobeNewsWire • 01/18/23
USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe GastroparesisGlobeNewsWire • 12/07/22
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®GlobeNewsWire • 11/30/22
Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific MeetingGlobeNewsWire • 10/20/22